CompletedNCT01250223
Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study)
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Associazione Angela Serra per la ricerca sul cancro
- Principal Investigator
- Massimo Federico, MDDip. Oncologia, Ematologia e Patologie dell'Apparato Respiratorio - Università di Modena e Reggio Emilia, Modena, Italy
- Enrollment
- 1093 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2003 – 2016
Study locations (30)
- Northwestern University Feinberg School of Medicine - Department of Hematology/Oncology, Chicago, Illinois, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Academia Nacional de Medicina - Oncohematology Department, Instituto de Investigaciones Hematologicas, Buenos Aires, Argentina
- Centro de Internacion e Investigacion Clinica "Angelica Ocampo" - Hematologia, Buenos Aires, Argentina
- Charles University General Hospital - Ist Dept Medicine, Prague, Czechia
- Centre Hospitalier Universitaire - Hématologie, Besançon, France
- Institut Bergonié Comprehensive Cancer Center, Bordeaux, France
- Centre Jean Bernard, Clinique Victor Hugo, Le Mans, France
- Centre Hospitalier Univeristaire - Hématologie clinique, Nantes, France
- Hopital caremeau - Service de Medecine Interne B, Nîmes, France
- CHRU Bretonneau - Oncologie medicale, Tours, France
- Presidio Spedali Civili, Brescia, BS, Italy
- Azienda Ospedaliera S. Croce e Carle, Cuneo, CN, Italy
- Azienda O.U. Vittorio Emanuele-Ferrarotto-S. Bambino, Catania, CT, Italy
- +15 more locations on ClinicalTrials.gov
Collaborators
Fondazione Italiana Linfomi - ETS · The International Non-Hodgkin Lymphoma Prognostic Factor Project
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01250223 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGNANCT07126678Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGEARLY PHASE1NCT06976437A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsYANRU WANG
- RECRUITINGNCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE1NCT07093073Clinical Study of U01（ssCART-19） in Patients With B-Cell LymphomaShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- RECRUITINGPHASE2NCT06959732Zanubrutinib Combined With G-CVP in Previously Untreated FLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT06662227Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsWondercel Biotech (ShenZhen)
- RECRUITINGPHASE3NCT06549595A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsAstraZeneca